Mesoblast (NASDAQ:MESO) Trading Down 5.5% – Should You Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) traded down 5.5% during trading on Thursday . The company traded as low as $14.85 and last traded at $14.9350. 50,806 shares were traded during trading, a decline of 80% from the average session volume of 254,950 shares. The stock had previously closed at $15.80.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Mesoblast Price Performance

The stock’s 50-day moving average price is $16.19 and its 200 day moving average price is $16.88. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -16.83 and a beta of 2.19. The company has a quick ratio of 1.41, a current ratio of 1.58 and a debt-to-equity ratio of 0.10.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) EPS for the quarter. The business had revenue of $25.67 million for the quarter. Equities research analysts expect that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in shares of Mesoblast in the 1st quarter valued at approximately $3,209,000. Creative Planning acquired a new position in Mesoblast in the second quarter valued at approximately $141,000. Raymond James Financial Inc. acquired a new position in Mesoblast in the second quarter valued at approximately $86,000. China Universal Asset Management Co. Ltd. grew its position in Mesoblast by 33.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,124 shares of the company’s stock worth $99,000 after acquiring an additional 2,302 shares during the period. Finally, Farther Finance Advisors LLC acquired a new stake in Mesoblast during the third quarter worth $58,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.